
Opinion|Videos|May 12, 2025
The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
Panelists discuss how evaluating a renal mass requires considering multiple factors, including patient expectations, comorbidities, life expectancy, tumor characteristics such as size and enhancement patterns, and predictive models to help guide decision-making.
Advertisement
Episodes in this series

Clinical Challenges in Renal Mass Evaluation
Main Discussion Topics:
- Multiple factors influence management decisions, including patient expectations, comorbidities, life expectancy, and tumor characteristics.
- Tumor assessment includes size, growth kinetics, and enhancement characteristics.
- Predictive models help assess patient longevity and tumor behavior.
Key Points for Physicians:
- Comprehensive assessment requires consideration of patient factors and tumor characteristics.
- Enhancement patterns on imaging provide valuable diagnostic information.
- Existing predictive models can help guide clinical decision-making.
Notable Insights:
Decision-making for renal masses requires a multifaceted approach that integrates patient-specific factors with tumor radiographic characteristics.
Clinical Significance:
A systematic approach that considers both patient factors and tumor characteristics leads to more appropriate management decisions for renal masses.
Advertisement
Related to this article

Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.

A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.

The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.

The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
4
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
5

